This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic radiosurgery and to see how well it works compared to whole-brain radiation therapy or stereotactic radiosurgery alone in treating patients with breast cancer or other cancers (such as lung cancer or melanoma) that have spread to the brain. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Whole-brain radiation therapy uses high energy x-rays deliver radiation to the entire brain to treat tumors that can and cannot be seen. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known whether giving RO4929097 together with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells ...

This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic radiosurgery and to see how well it works compared to whole-brain radiation therapy or stereotactic radiosurgery alone in treating patients with breast cancer or other cancers (such as lung cancer or melanoma) that have spread to the brain. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Whole-brain radiation therapy uses high energy x-rays deliver radiation to the entire brain to treat tumors that can and cannot be seen. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known whether giving RO4929097 together with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells ...

Whole-brain radiation therapy (WBRT) delivers radiation treatments to the entire brain over a period of many weeks. WBRT is typically used if there are more than a few areas of cancer in the brain. WBRT helps to shrink the tumors and improve symptoms. WBRT also may be used in place of, or in addition to, stereotactic radiosurgery. The side effects of WBRT include thought and memory problems, so its important to have a conversation with your doctor to weigh the risks and benefits of WBRT in your situation. If you have HER2-positive breast cancer that has moved into the brain, you may be able to delay whole-brain radiation therapy by using the combination of Tykerb (chemical name: lapatinib) and Xeloda (chemical name: capecitabine). For more information, see Targeted Therapies to Treat Recurrent and Metastatic Breast Cancer. ...

This phase I trial studies the side effects and best dose of trametinib with or without whole brain radiation therapy in treating patients with brain metastases. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Drugs, such as trametinib, may make tumor cells more sensitive to radiation therapy. Giving trametinib with whole brain radiation therapy may be an effective treatment for brain metastases.

Although targeted therapies have produced dramatic advances in our ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits in the brain, but the best technique to deliver radiation can be controversial. Whole-brain radiation therapy, as its name suggest, treats the entire brain but can be associated with notable cognitive side effects. Another strategy, radiosurgery, directs highly-focused radiation only to the sites of metastasis, largely sparing the normal brain. The challenge has been to define in which circumstances each technique is best. The debate has centered on the number of brain metastases, with the field generally agreeing that with three or fewer deposits, radiosurgery is the preferred approach, and then switching to the use of whole-brain radiation to treat four or more deposits.. A University of Colorado Cancer Center study published today in the Journal of Thoracic Oncology ...

TY - JOUR. T1 - Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. AU - Pan, Edward. AU - Yu, Daohai. AU - Zhao, Xiuhua. AU - Neuger, Anthony. AU - Smith, Pamela. AU - Chinnaiyan, Prakash. AU - Yu, Hsiang Hsuan M.ichael. PY - 2014/9/1. Y1 - 2014/9/1. N2 - A phase I study was conducted to evaluate the dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD)/recommended phase II dose of bendamustine with concurrent whole brain radiation (WBR) in patients with brain metastases (BM) from solid tumors. Four doses of intravenous weekly bendamustine were administered with 3 weeks of WBR at three dose levels (60, 80, and 100 mg/m(2)) according to a standard 3 + 3 phase I design. A total of 12 patients with solid tumor BM were enrolled in the study (six with non-small cell lung cancer, four with melanoma, one with breast cancer, and one with neuroendocrine carcinoma). The first two dose levels had three ...

Clin Cancer Res. 2004 Oct 1;10(19):6411-7. A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Metz JM¹, Smith D, Mick R, Lustig R, Mitchell J, Cherakuri M, Glatstein E, Hahn SM. ¹Department of Radiation Oncology, University of Pennsylvania, Philadelphia Abstract PURPOSE: Complete alopecia is a universal complication of whole brain radiation therapy which contributes to patient anxiety over treatment. Tempol, a nitroxide radioprotector, has been shown to protect against radiation-induced alopecia in an animal model. This phase Ib study was designed to evaluate the safety and side effect profile of topical Tempol in patients with brain metastases being treated with whole brain radiotherapy. EXPERIMENTAL DESIGN: Twelve patients with metastatic cancer to the brain were enrolled in the study between October 2000 and February 2003. Tempol (70 mg/ml concentration solution) was applied topically to the scalp 15 minutes before and washed off immediately

The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy,

TY - CHAP. T1 - Simultaneously integrated boost to multiple brain metastases during whole brain radiation therapy-hippocampal avoidance. AU - Gutiérrez, Alonso N.. AU - Tomé, Wolfgang A.. AU - Ghia, Amol. AU - Thomas, Sayana. AU - Cannon, George. AU - Khuntia, Deepak. AU - Kuo, John S.. AU - Mehta, Minesh. PY - 2010/3/19. Y1 - 2010/3/19. N2 - Purpose: To evaluate the feasibility of delivering a radiosurgery-quality integrated boost to visible brain metastases combined with hippocampal sparing whole brain radiotherapy using helical tomotherapy. Materials and Methods: Ten patients were planned on helical tomotherapy using MR-CT fusion-defined target and normal structure contours. Individually contoured hippocampi were used as conformal avoidance structures and limited to a mean-NTD2 of 6 Gy, where NTD2 denotes the normalized total dose delivered in 2 Gy fractions assuming an α/β-ratio of 2 Gy. A whole brain dose of 32.25 Gy and simultaneous boost doses to brain metastases of either 63.0 Gy (, ...

Whole brain radiotherapy (WBRT) is a palliative option for patients with brain metastases that alleviates symptoms, decreases the use of corticosteroids needed to control tumor-associated edema, and potentially improves overall survival. It has been reported to increase the risk of cognitive decline. McTyre, E; Scott, J; Chinnaiyan, P (2013). Whole brain radiotherapy for brain metastasis. Surg Neurol Int. 4: S236-44. doi:10.4103/2152-7806.111301. PMC 3656558 . PMID 23717795. Whole-Brain Radiotherapy: Risks Worth Benefit?. Medscape.com. Retrieved August 20, 2015 ...

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5 ...

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5 ...

abstractNote = {A 12 year-old girl was treated with prophylactic cranial irradiation for acute lymphoblastic leukaemia (ALL). At the age of 39, she was admitted to our hospital for status epilepticus. Computed tomography demonstrated two, enhancing bilateral sided intracranial tumors. After surgery, this patient presented meningiomas which histologically, were of the meningothelial type. The high cure rate in childhood ALL, attributable to aggressive chemotherapy and prophylactic cranial irradiation, is capable of inducing secondary brain tumor. Twelve cases of high-dose radiation-induced meningioma following ALL are also reviewed. (author ...

To retrospectively access outcome and toxicity of whole brain radiotherapy (WBRT) in patients with multiple brain metastases (BM) from malignant melanoma (MM). Results of 87 patients (median age 58 years; 35 female, 52 male) treated by WBRT for BM of MM between 2000 and 2011 were reviewed. Total dose applied was either 30 Gy in 10 fractions (n = 56) or 40 Gy in 20 fractions (n = 31). All but 9 patients suffered from extra-cerebral metastases. Prior surgical resection of BM was performed in 18 patients, salvage stereotactic radiosurgery in 13 patients. Mean follow-up was 8 months (range, 0-57 months), the 6- and 12-months overall-(OS) survival rates were 29.2% and 16.5%, respectively. The median OS was 3.5 months. In cerebral follow-up imaging 6 (11) patients showed a complete (partial) remission, while 11 (17) patients had stable disease (intra-cerebral tumor progression). In comparison of total dose, the group treated with 40 Gy in 20 fractions achieved a significant longer OS (p = 0.003, median 3.1 vs

In patients who had undergone surgery for brain metastases, the rate of recurrence at the resected site was similar between patients who received adjuvant whole-brain radiotherapy vs those who underwent adjuvant localized radiotherapy, according to a retrospective study by Hsieh et al in the journal Neurosurgery. However, localized radiotherapy was associated with a higher incidence of distant metastases.. Surgery followed by adjuvant whole-brain radiotherapy is a well-established treatment for brain metastases, particularly in patients who have a limited number of brain metastases. Yet discussions continue as to whether these patients require whole-brain radiotherapy or can be treated with localized radiotherapy. Localized radiotherapy is associated with fewer side effects compared with whole-brain radiotherapy, but some studies have documented an association with an increased risk for development of new intracranial metastases.. Thus, the investigators conducted a study to examine the rate of ...

In this randomised study, in patients with 4-10 brain metastases (BM), the standard treatment of whole brain radiotherapy (WBRT) is compared to …

Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia | Perel, Yves; Leverger, Guy; Carrere, Anne; Caudry, Michel; Garabedian, Erea Noel; Ansoborlo, Sophie; Vergnes, Pierre | download | BookSC. Download books for free. Find books

Patients with brain metastases from lung cancer have poor prognoses and short survival time, and they are often excluded from clinical trials. Whole-cranial irradiation is considered to be the standard treatment, but its efficacy is not satisfactory. The purpose of this phase II clinical trial was to evaluate the preliminary efficacy and safety of the treatment of whole-brain irradiation plus three-dimensional conformal boost combined with concurrent topotecan for the patients with brain metastases from lung cancer. Patients with brain metastasis from lung cancer received concurrent chemotherapy and radiotherapy: conventional fractionated whole-brain irradiation, 2 fields/time, 1 fraction/day, 2 Gy/fraction, 5 times/week, and DT 40 Gy/20 fractions; for the patients with ≤ 3 lesions with diameter ≥ 2 cm, a three-dimensional (3-D) conformal localised boost was given to increase the dosage to 56-60 Gy; and during radiotherapy, concurrent chemotherapy with topotecan was given (the chemoradiotherapy

Surgical resection plus WBRT versus surgical resection alone Level 1 Surgical resection followed by WBRT represents a superior treatment modality, in terms of improving tumor control at the original site of the metastasis and in the brain overall, when compared to surgical resection alone. Surgical …

Although targeted therapies have produced dramatic advances in our ability to control some types of advanced lung cancer, growth of the disease in the brain remains a major problem. Radiation is often used to treat deposits ...

SAPPORO, Japan - Adding whole-brain irradiation to stereotactic radiosurgery does not improve survival of patients with metastatic brain cancer, but it may reduce recurrence of the metastases, r

The results of a recently reported clinical study at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco demonstrate that thoracic radiation improves survival and reduces cancer recurrence when added to prophylactic cranial irradiation in patients with extended-stage small cell lung cancer.(1) Small-cell lung cancer (SCLC) is a fast-growing […]. ...

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading ...

PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.. Participants using ASTROs online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.. The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.. ...

My husand has been diagnosed with brain, liver, lung, colon,& right adrenal gland melanoma cancer. They have said 6-8 weeks to survive if treatment didnt work and only maybe 6 months if it does. We are Christians and believe in miracles.. It all started from a mole on his back. He had it removed in 2007 and a few lymph nodes under his arm. All was well, we thought, until my husband started feeling bad about a month ago. He was gagging in the morning like he had post nasal drip. He felt crummy overall. He then got a pain in is lower right belly. We thought a appendicitis. We went to the Dr. and they did a series of CAT/PET/MRI scans. I cant remember in what order when.. Anyways, they then told use that he had all this extensive cancer throughout the body. They thought the brain should be addressed first. He had 10 treatments of WBRT (whole brain radiation therapy. He was sent for concult with renowned cancer specialist Dr. Thompson from SCCA, UofW, and Fred Hutchinson. He does clinical trial ...

Treating brain tumors with whole brain radiation therapy can damage healthy brain tissue, but a new study in mice reveals that limiting the oxygen supply, or hypoxia, can alleviate some of the cognitive impairment caused ...

Whole brain radiation therapy costs mice some of their cognitive abilities, but treatment with low-oxygen air revives their reasoning skills.

Whole brain radiation therapy costs mice some of their cognitive abilities, but treatment with low-oxygen air revives their reasoning skills.

Exercise can help improve both memory and mood after whole-brain radiation treatment, thats the conclusion of a new study in rodents.

If the study is suitable for you, you will commence treatment with chemotherapy and thoracic (chest) radiotherapy and prophylactic cranial irradiation (PCI/ brain) radiotherapy which are the standard of care treatment for SCLC. Following completion of the chemotherapy and radiotherapy part of your treatment you will have a CT scan to see if your cancer is shrinking or growing. If your cancer has grown your consulting doctor will discuss the most suitable treatment for you at that time ...

Bennette,. Every person handles things differently so I dont think anyone can say exactly how your mom will do with the WBRT. My husband did 2 weeks of daily but he is also taking 2 chemo treatments at the same time. He was just tired at first but then all of a sudden he got deathly ill, throwing up, diarrhea, not knowing he was even going, then didnt know me either. He ended up in the hospital for a week too week to move. His head was very scaly and irritated even with prescription oil, sween cream, his hand was grabbing at it all the time and rubbing it, then his ears were affected, behind the ear became very raw, his ears were swollen almost completely shut. He lost his hearing for about 2 weeks. I am not trying to scare you just letting you know what could happen...After about a month, his skin is like baby soft skin all the burns and scaliness is gone, his hearing is back. He walks with a cane. The doctors opinion is that the combination of chemo we were using coupled with the radiation ...

This past Friday Anna went in for an unplanned MRI. She was having some symptoms that concerned her doctor. The breast cancer in Annas brain has grown exponentially. The three most recent tumours that had shrunk initially after whole brain radiation have grown again, along with the initial tumour from last January when she had…

TY - JOUR. T1 - Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy. T2 - A Propensity Score Analysis and Predictors of Care for Patients With Brain Metastases From Breast Cancer. AU - Mainwaring, Walker. AU - Bowers, John. AU - Pham, Ngoc. AU - Pezzi, Todd. AU - Shukla, Mihir. AU - Bonnen, Mark. AU - Ludwig, Michelle. PY - 2019/4. Y1 - 2019/4. N2 - Background: Metastases to the brain occur in 10%-16% of patients with breast cancer, with incidence reportedly increasing. Historically, brain metastases (BM) have been treated with whole-brain radiation therapy (WBRT), but stereotactic radiosurgery (SRS) is an increasingly favored treatment option. In this study we used a population-level database to compare patterns of care and survival between WBRT and SRS for BM from breast cancer. Materials and Methods: The National Cancer Database was used to select patients treated with radiation for BM from primary breast cancer. Groups were classified on the basis of the modality of radiation ...

TY - JOUR. T1 - Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain. AU - Stewart, David J.. AU - Feun, Lynn G.. AU - Maor, Moshe. AU - Leavens, Milam. AU - Burgess, M. Andrew. AU - Benjamin, Robert S.. AU - Bodey, Gerald P.. N1 - Copyright: Copyright 2007 Elsevier B.V., All rights reserved.. PY - 1983/3. Y1 - 1983/3. N2 - Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation. Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of ...

Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy Academic Article ...

TY - JOUR. T1 - An instrument for estimating the 6-month survival probability after whole-brain irradiation alone for cerebral metastases from gynecological cancer. AU - Janssen, Stefan. AU - Hansen, Heinke C.. AU - Schild, Steven E.. AU - Rades, Dirk. PY - 2018/6/1. Y1 - 2018/6/1. N2 - Background/Aim: Patients with cerebral metastases from gynecological cancer who receive whole-brain irradiation (WBI) alone require personalized therapy. This study contributes to personalized care by creating an instrument to predict 6-month survival probability. Patients and Methods: In 49 patients, six pre-treatment variables, namely age, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of cerebral metastases, metastasis outside the brain, and interval between diagnosis of gynecological cancer and WBI, were analyzed for survival. Results: Of the six pre-treatment variables, ECOG-PS was significantly associated with survival (p=0.014) and metastasis outside the brain ...

Munich, February 3, 2017-In support of World Cancer Day 2017, which aims to bring global attention to cancer, Brainlab, a leader in cancer-fighting technologies, raises awareness about metastatic brain cancer and the revolutionary new methods being used to treat the disease. According to the World Health Organization (WHO), 14 million new cases of cancer are diagnosed every year, with that number expected to rise by 70% over the next two decades. Cancers of the lung, breast, skin, colon and kidney present the highest risk of metastasizing to the brain.. As treatments improve, in combination with early detection, cancer patients are living longer, resulting in higher incidence of brain metastases, according to the American Brain Tumor Association (ABTA). One of the most prevalent procedures for treating multiple brain metastases is whole brain radiation therapy (WBRT) despite increasing evidence that WBRT can lead to significant cognitive side effects and the existence of alternative, less severe ...

TY - JOUR. T1 - Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933). T2 - A phase II multi-institutional trial. AU - Gondi, Vinai. AU - Pugh, Stephanie L.. AU - Tome, Wolfgang A.. AU - Caine, Chip. AU - Corn, Ben. AU - Kanner, Andrew. AU - Rowley, Howard. AU - Kundapur, Vijayananda. AU - DeNittis, Albert. AU - Greenspoon, Jeffrey N.. AU - Konski, Andre A.. AU - Bauman, Glenn S.. AU - Shah, Sunjay. AU - Shi, Wenyin. AU - Wendland, Merideth. AU - Kachnic, Lisa. AU - Mehta, Minesh P.. N1 - Publisher Copyright: © 2014 by American Society of Clinical Oncology. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.. PY - 2014/12/1. Y1 - 2014/12/1. N2 - Purpose: Hippocampal neural stem-cell injury during whole-brain radiotherapy (WBRT) may play a role in memory decline. Intensity-modulated radiotherapy can be used to avoid conformally the hippocampal neural stem-cell compartment during ...

To assess the role of leukapheresis and cranial irradiation in reducing the incidence of intracranial hemorrhage (ICH) and early death in patients with hyperleukocytic acute myeloid leukemia (AML) and the impact of such treatment on survival. This study retrospectively analyzed the records of 75 patients with hyperleukocytic AML who had a white cell count over 100,000/microL. All patients had de novo AML except for two with therapy-related AML. Various factors were assessed for their impact on morbidity and mortality, particularly the role of pre-induction leukapharesis and cranial irradiation. The most significant risk factors for ICH were the presence of two or more symptoms of leukostasis (odds ratios [OR] 10.6, 95% CI: 2.67-42.02; P = 0.001) and respiratory distress (OR 5.41, 95% CI: 1.44-20.32, P = 0.012). The most significant risk factors for early death were age ,or= 65 (OR 4.21, 95% CI: 1.45-12.21, P = 0.008), respiratory failure (OR 3.34, 95% CI: 1.24-9.50, P = 0.018), and two or more ...

OBJECTIVE This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months. METHODS Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)-based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9. RESULTS In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0.65-1.06], p = 0.14) and significantly PFS from last HDMTX (25.5 vs 12.0 months, HR 0.65 [95% CI 0.5-0.83], p = 0.001), but without OS prolongation (35.6 vs 37.1 months, HR 1.03 [95% CI 0.79-1.35], p = 0.82). In the intent-to-treat population (n = 410), there was a prolongation by WBRT of both PFS (15.4 vs 9.9 ...

The aim of this study was to compare outcomes of postoperative whole brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) alone in patients with resected brain metastases (BM). We reviewe

Radiation therapyRadiation therapy (or radiotherapy) is used on painful bony areas, in high disease burdens, or as part of the preparations for a bone marrow transplant (total body irradiation). Radiation in the form of whole-brain radiation is also used for central nervous system prophylaxis, to prevent recurrence of leukemia in the brain. Whole-brain prophylaxis radiation used to be a common method in treatment of childrens ALL. Recent studies showed that CNS chemotherapy provided results as favorable but with less developmental side-effects. As a result, the use of whole-brain radiation has been more limited. Most specialists in adult leukemia have abandoned the use of radiation therapy for CNS prophylaxis, instead using intrathecal chemotherapy. Biological therapyFor some subtypes of relapsed ALL, aiming at biological targets such as the proteasome, in combination with chemotherapy, has given promising results in clinical trials. Selection of biological targets on the basis of their ...

The single-arm, phase II study was a multi-institutional, international clinical trial in the U.S. and Canada, conducted through the Radiation Therapy Oncology Group (RTOG). Researchers compared the study group to a historical control group of patients who had received WBRT without hippocampal avoidance in the PCI-P-120-9801 phase III trial (Li 2007). This study enrolled 113 adult patients from 2011 through 2013 who had a measurable brain metastasis outside a 5-mm margin around the hippocampus. Of those patients, 100 were analyzable and 76 percent were categorized as recursive partitioning analysis (RPA) class II. All patients received hippocampal avoidance whole-brain radiotherapy (HA-WBRT) to 30 Gy in 10 fractions. In all analyzable patients, the dose received by the entirety of the hippocampus did not exceed 10 Gy, and the maximum dose did not exceed 17 Gy. Patients were assessed using the Hopkins Verbal Learning Test - Delayed Recall (HVLT-DR), the HVLT - Recall (HVLT-R) and the HVLT - ...

Twelve patients who had brain metastases and received fractionated whole brain radiation therapy (WBRT) (30 or 37.5G) were included in the study. Diffusion weighted images were acquired pre RT, end of RT, and 1-month post-RT. The fornix, cingulum and corpus callosum were extracted from diffusion weighted images by combining fiber tracking and segmentation methods based upon characteristics of the fiber bundles. The ingulum was segmented by a seed-based tractography, the fornix by an ROI-based tractography, and the corpus callosum by a level-set segmentation algorithm. The radiation-induced longitudinal changes in diffusion indices of the structures were evaluated ...

The majority (40-60%) of patients with metastatic her2 positive breast cancer develop brain metastases at some point in their disease course. One should maintain a low threshold for imaging the brain if a patient reports any neurologic symptoms, even if subtle. Oligometastases should be considered for surgical excision or radiotactic surgery followed by whole brain radiotherapy. Retreatment of progressive brain metastases with further radiation is sometimes feasible and beneficial, if the disease was controlled for an extended period (generally at least ten months) after initial radiotherapy. Several systemic drugs have some penetration into the blood brain barrier and may enhance control of brain metastases from breast cancer. These include capecitabine, lapatinib, anthracyclines, and cisplatin. While some other drugs have been used to treat primary brain tumors, their ability to control brain metastases of breast cancer origin has been disappointing ...

A national network of investigators, cancer care providers, and other institutions that brings cancer clinical trials and cancer care research to a persons own community.

Inclusion Criteria: Part A • With advanced solid malignancies who are not eligible for standard therapy or for whom standard therapy has failed Part B • With histologically or cytologically confirmed NSCLC of stage IIIB or IV (per 7th International Association for the Study of Lung Cancer classification) that has progressed after one line of platinum containing doublet chemotherapy Part A and B - Willingness and feasibility to provide a tumor biopsy sample both at screening and during treatment (If archived tumor material not older than 1 year is available, then the screening biopsy will not be performed). - Participants with prior radiation therapy must have measurable disease in non-irradiated sites or documented evidence of progression within the radiation field. - With known central nervous system (CNS) must have completed primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection) and must have remained clinically stable, ...

HOUSTON--Controversy continues to shroud the issue of how single and multiple brain metastases should be treated, Moshe H. Maor, MD, said at a symposium on CNS cancer, sponsored by The University of Texas M.D. Anderson Cancer Center, where he is a radiation oncologist. 1

Vanna Dest, MSN, APRN-BC, AOCN, Oncology Nurse Practitioner/Manager, Oncology APP, Yale-New Haven Hospital, discusses the side effects of treatment with brain radiation.

CARR-13c]R. Soffietti, Kocher, M., Abacioglu, M., Villa, S., Fauchon, F., Baumert, G., Fariselli, L., Tzuk-Shina, T., Kortmann, R., Carrie, C., Benhassel, M., Kouri, M., Valeinis, E., van den Berge, D., Mueller, R., Tridello, G., Collette, L., and Bottomley, A., A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 31, no. 1, pp. 65-72, 2013. ...

Purpose Hippocampal neural stem-cell injury during whole-brain radiotherapy (WBRT) may play a role in memory decline. Intensity-modulated radiotherapy can be ...

keď chodím do školy alebo niekde ráno, tak sa snažím medzi 23:00 až 00:00 a keď nie, tak medzi 00:00 až 1:00 ale väčšinou keď mam na ďalší deň skúšku a musím sa učiť a nestíham tak potiahnem aj do druhej a vstávam o piatej káva a ideme sa učiť :D ...